Busulfan Injection shortage
Busulfan Injection is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 22, 2026.
Viatris is permanently stopping its busulfan injection, the chemotherapy used before bone marrow transplants. The same medicine — including Busulfex — is still listed by other makers such as Hospira, Accord Healthcare, Sagent, and Otsuka.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Busulfan Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Oct 24, 2025Currently in shortage1 of 1 product affected.
-
Oct 24, 2025First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Mylan Institutional, a Viatris Company 📞 800-796-9526 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Busulfan, Injection, 6 mg/1 mL (NDC 67457-893-08) | — | — | Discontinuation of the manufacture of the drug. | — |
These rows are manufacturer reports to the FDA for Busulfan Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Busulfan Injection? options further down this page.
Why is Busulfan Injection in shortage?
Mylan Institutional (a Viatris company) has reported to the FDA that it is permanently stopping the manufacturing of its busulfan injection — specifically the 6 mg/1 mL vial (NDC 67457-893-08). No specific reason for this decision was shared publicly with the FDA, so unfortunately I can't tell you exactly why they made this choice.
It's worth knowing that this report only reflects what Mylan Institutional submitted — it covers their product specifically, not every version of busulfan injection that exists on the market.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Busulfan Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Busulfan Injection?
Busulfan Injection is currently on the FDA drug-shortage list. I know seeing this can feel unsettling, so let me walk you through what it means and what comes next.
This shortage report covers the 6 mg/1 mL strength, and right now that strength has no available source from the manufacturer who filed this report. The reason given is that the maker, Mylan Institutional (a Viatris Company), is discontinuing the manufacture of this product. Because this is listed as "to be discontinued," the supply problem from this manufacturer may be permanent — which makes a conversation with your care team the right next step.
I want to be clear that this report reflects only the one manufacturer who filed it. Other companies still make busulfan injection, so the medicine itself is not gone.
Here is what you can do:
- Do not stop, skip, or change any doses on your own.
- Ask your pharmacy or treatment center to check wholesalers and other makers — the same medicine (busulfan injection 6 mg/mL) is also listed from Hospira, Accord Healthcare, Sagent, Otsuka (Busulfex), Amneal, and Meitheal. It may not be in local stock, but they may be able to source it.
- If your exact product cannot be found, ask your prescriber or pharmacist about a suitable option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general national information and may not match your local stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Busulfan Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Busulfan Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Busulfan | BUSULFAN 6 mg/mL | Injection, Solution · Intravenous | Hospira, Inc. | 00409-1112-01 |
| Busulfan | BUSULFAN 6 mg/mL | Injection · Intravenous | Accord Healthcare, Inc | 16729-0351-92 |
| Busulfan | BUSULFAN 6 mg/mL | Injection, Solution, Concentrate · Intravenous | Sagent Pharmaceuticals | 25021-0241-10 |
| Busulfex | BUSULFAN 6 mg/mL | Injection · Intravenous | Otsuka America Pharmaceutical, Inc. | 59148-0070-91 |
| Busulfan | BUSULFAN 6 mg/mL | Injection · Intravenous | Amneal Pharmaceuticals LLC | 70121-1244-07 |
| Busulfan | BUSULFAN 6 mg/mL | Injection, Solution · Intravenous | Meitheal Pharmaceuticals Inc. | 71288-0116-11 |
Alternative dosage forms of Busulfan
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 10 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Busulfan 6 mg/mL | Hospira, | 1 vial | — | AP | FDA listed |
| Busulfan 6 mg/mL | Accord | 8 vials | — | AP | FDA listed |
| Busulfan 6 mg/mL | Sagent | 8 vials | — | AP | FDA listed |
| Busulfan 6 mg/mL | Pharmascience | 8 vials | — | AP | FDA listed |
| Busulfan 6 mg/mL | Eugia | 8 vials | — | — | FDA listed |
| Busulfex 6 mg/mL | Otsuka | 1 vial | — | AP | Discontinued |
| Busulfan 6 mg/mL | Amneal | 8 vials | — | AP | FDA listed |
| Busulfan 6 mg/mL | Meitheal | 8 vials | — | AP | FDA listed |
| Busulfan 6 mg/mL | Meitheal | 8 vials | — | AP | FDA listed |
| Busulfan 6 mg/mL | Mylan | 8 vials | — | — | Discontinued |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Busulfan Injection — that fall in the same broad treatment class (antineoplastic - alkylating agents) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other hematology shortages
Busulfan Injection shortage FAQs
Is Busulfan Injection in shortage?
Which products are affected?
When will Busulfan Injection be available again?
Can I still get Busulfan somewhere?
What should I do if I take Busulfan Injection?
Still have a question about the Busulfan Injection shortage?
Ask a pharmacist about this shortage →View Busulfan Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.